One- and two-year clinical outcomes of treatment with resorbable magnesium scaffolds for coronary artery disease: the prospective, international, multicentre BIOSOLVE-IV registry
EuroIntervention · 2023-06 · 19 (3) · 232-239
DOI: 10.4244/eij-d-22-01069 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift EuroIntervention, 2023-06. Verfasst von Adrian Wlodarczak und 10 weiteren Autor:innen. Beteiligte Einrichtung: Copper Health Center, Lubin, Poland. Hauptthemen laut MEDLINE: Coronary Artery Disease, Non-ST Elevated Myocardial Infarction, Diabetes Mellitus, Thrombosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Bioresorbable scaffolds have been developed to overcome the limitations of drug-eluting stents and to reduce long-term adverse events. AIMS: We aimed to assess the long-term safety and efficacy of a sirolimus-eluting resorbable magnesium scaffold to ensure its safe rollout into clinical routine. METHODS: BIOSOLVE-IV is a prospective, international, multicentre registry including more than 100 centres in Europe, Asia, and Asia-Pacific. Enrolment started directly after the commercialisation of the device. Follow-up assessments are scheduled at 6 and 12 months, and annually for up to 5 years; we herein report the 24-month outcomes. RESULTS: Overall, 2,066 patients with 2,154 lesions were enrolled. Patients were 61.9±10.5 years old, 21.6% had diabetes, and 18.5% had non-ST-elevation myocardial infarction (NSTEMI). Lesions were 14.8±4.0 mm long with a reference vessel diameter of 3.2±0.3 mm. Device and procedure success were 97.5%, and 99.1%, respectively. The 24-month target lesion failure (TLF) rate was 6.8%, mainly consisting of clinically driven target lesion revascularisations (6.0%). Patients with NSTEMI had significantly higher TLF rates than those without (9.3% vs 6.2%; p=0.025), whereas there were no significant differences observed for patients with diabetes or with type B2/C lesions (a 24-month TLF rate of 7.0% and 7.9%, respectively). The 24-month rate of definite or probable scaffold thrombosis was 0.8%. Half of the scaffold thromboses occurred after premature discontinuation of antiplatelet/anticoagulation therapy, and only one scaffold thrombosis occurred beyond the 6-month follow-up, on day 391. CONCLUSIONS: The BIOSOLVE-IV registry showed good safety and efficacy outcomes, confirming a safe rollout of the Magmaris into clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Copper Health Center, Lubin, Poland.
- Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy and Centro Cardiologico Monzino, IRCCS, Milan, Italy.
- Cardiovascular Center Oberallgäu-Kempten, Kempten, Germany.
- Department of Cardiovascular Medicine, University Hospitals Leuven, Leuven, Belgium.
- Department of Cardiology, Cairns Hospital, Cairns, QLD, Australia.
- Department of Cardiology, HerzZentrum Westfalen, Klinikum Westfalen, Dortmund, Germany.
Zitieren
APA
Wlodarczak, A., Montorsi, P., Torzewski, J., Bennett, J., Starmer, G., Buck, T., Haude, M., Moccetti, M., Wiemer, M., Lee, M. K., & Verheye, S. (2023). One- and two-year clinical outcomes of treatment with resorbable magnesium scaffolds for coronary artery disease: the prospective, international, multicentre BIOSOLVE-IV registry. EuroIntervention, 19(3), 232-239. https://doi.org/10.4244/eij-d-22-01069
Vancouver
Wlodarczak A, Montorsi P, Torzewski J, Bennett J, Starmer G, Buck T, et al. One- and two-year clinical outcomes of treatment with resorbable magnesium scaffolds for coronary artery disease: the prospective, international, multicentre BIOSOLVE-IV registry. EuroIntervention. 2023;19(3):232-239. doi:10.4244/eij-d-22-01069
BibTeX
@article{Wlodarczak2023,
author = {Wlodarczak, Adrian and Montorsi, Piero and Torzewski, Jan and Bennett, Johan and Starmer, Gregory and Buck, Thomas and Haude, Michael and Moccetti, Marco and Wiemer, Marcus and Lee, Michael-Kang-Yin and Verheye, Stefan},
title = {One- and two-year clinical outcomes of treatment with resorbable magnesium scaffolds for coronary artery disease: the prospective, international, multicentre BIOSOLVE-IV registry},
journal = {EuroIntervention},
year = {2023},
volume = {19},
number = {3},
pages = {232--239},
doi = {10.4244/eij-d-22-01069}
}
EUVIMED